Chronic Myeloid Leukemia: What Is the Best Strategy to Start and Monitor Treatment Outside Academic Centers?
- 30 January 2018
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 20 (1) , 4
Abstract
The introduction of tyrosine kinase inhibitors (TKI) has dramatically changed the outcome of chronic myeloid leukemia (CML). Over the last decade, imatinib positioned itself as the gold standard of care, until second-generation TKIs were introduced as first-line treatment. Multiple therapeutic options available today in CML make the decision of the first-line therapy a difficult choice. However, a gap still exists, in the management of CML outside academic centers. Important advances in molecular monitoring have been developed worldwide; nevertheless, monitoring in the “real world” continues to be a challenge in part because international scale (IS) standardized laboratories are not available worldwide, and also because physicians still have some resource barriers and lack of familiarity restricting guideline adoption and consider optimal molecular monitoring a challenge. This review addresses CML first-line treatment, monitoring aspects and giving practical advice, identifying prognostic factors, and guiding management of CML for non-academic centers.Keywords
This publication has 35 references indexed in Scilit:
- Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLeukemia, 2016
- Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American CountryClinical Lymphoma Myeloma and Leukemia, 2016
- Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibratorsLeukemia, 2016
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLeukemia, 2016
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia, 2016
- How we will treat chronic myeloid leukemia in 2016Blood Reviews, 2015
- The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspectiveThe Lancet, 2014
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia, 2012
- Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaLeukemia, 2006
- Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBritish Journal of Haematology, 1999